Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 10/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31286312 | 0.85 | CA12 (0.62) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL9302636 | 0.85 | CA12 (0.62) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL718613 | 0.79 | CA12 (0.52) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL717450 | 0.79 | CA12 (0.59) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL25490046 | 0.77 | GRM5 (0.50) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL9304700 | 0.77 | CA12 (0.62) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL29978832 | 0.77 | GRM5 (0.50) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL935880 | 0.77 | CA12 (0.50) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL15540865 | 0.77 | CA12 (0.50) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL16618991 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-18 | — | — | US | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024128195-A1 | PEPTIDE PRODUCTION METHOD COMPRISING STEP FOR TRANSLATING AMINO ACID HAVING OXYGEN ATOM AT SPECIFIC POSITION | 中外製薬株式会社 | 2024-06-20 | — | — | WO | disclosed |
| CN-111479819-B | Method for preparing peptide and method for treating alkali | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| WO-2024101386-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | 中外製薬株式会社 | 2024-05-16 | — | — | WO | disclosed |
| WO-2024101402-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | 中外製薬株式会社 | 2024-05-16 | — | — | WO | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| WO-2024096023-A1 | METHOD FOR REMOVING DIBENZOFULVENE OR DIBENZOFULVENE DERIVATIVE | 中外製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2001068619-A1 | 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEX INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005390-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005391-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041505-A2 | ANTHRANILIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041994-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042022-A1 | BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042002-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | CA12 3001/4885CA2 2947/4885CA9 2489/4885 |
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | KRAS, G3BP1, G3BP2 | CA12 2761/4885CA2 3518/4885CA9 4225/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CA12 1113/4885CA2 2242/4885CA9 1496/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | CA12 894/4885CA2 985/4885CA9 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.